Drug-coated balloons (DCB) and drug-eluting stents (DES) are the two workhorses of modern anti-restenotic angioplasty. Both deliver an antiproliferative drug to the vessel wall to suppress the neointimal overgrowth that causes restenosis — but they embody opposite philosophies. A DES leaves a permanent scaffold coated with drug; a DCB delivers drug during a brief inflation and leaves nothing behind. Understanding where each excels is central to contemporary decisions in both coronary and peripheral intervention.
Two Mechanisms, One Goal
A drug-eluting stent is a metal scaffold whose polymer coating releases an antiproliferative agent (a -limus drug or paclitaxel) over weeks, holding the vessel open while suppressing restenosis. A drug-coated balloon is an angioplasty balloon whose surface carries a lipophilic drug (classically paclitaxel) transferred to the wall in a single 30–60 second inflation; no implant remains. Both attack restenosis; they differ in what is left in the artery afterward — and that difference drives selection.
Where DCB Shines: "Leave Nothing Behind"
The DCB advantage is the absence of a permanent implant. That matters most in three settings: in-stent restenosis, where adding yet another metal layer is undesirable; small vessels, where a stent's struts occupy a large fraction of the lumen; and bifurcations and diffuse disease, where stenting is mechanically awkward. In the peripheral arteries — femoropopliteal disease especially — DCBs preserve future options and avoid stent fracture in a mobile vessel. A shorter mandatory course of dual antiplatelet therapy is a further practical benefit for bleeding-prone patients.
Where DES Remains First Choice
When a lesion needs mechanical scaffolding, the stent wins. Acute vessel recoil, a flow-limiting dissection after balloon dilation, heavily calcified or long de novo lesions, and most large coronary vessels are DES territory — the scaffold is precisely the point. A frequent real-world hybrid is "DCB where possible, DES where necessary": treat with the balloon, and bail out to a stent only if dilation leaves recoil or dissection.
The INVAMED Extender and Atlas Platforms
INVAMED's coronary and cardiac intervention portfolio covers both philosophies: the Extender drug-coated PTA balloon and Extender paclitaxel drug-eluting PTCA balloon on the balloon side, and the Atlas cobalt-chromium coronary stent system on the scaffold side. Device and strategy selection are always the operator's decision based on lesion morphology and the Instructions for Use.
Frequently Asked Questions
What is the main difference between a drug-coated balloon and a drug-eluting stent?
A DES leaves a permanent drug-coated metal scaffold in the artery; a DCB delivers the drug during a brief inflation and leaves no implant behind.
When is a drug-coated balloon preferred?
In-stent restenosis, small vessels, bifurcations, diffuse disease, and peripheral (especially femoropopliteal) lesions where avoiding a permanent implant is advantageous.
Does a drug-coated balloon require dual antiplatelet therapy?
Generally a shorter course than a stent, because no implant is left to endothelialize — a benefit for patients at higher bleeding risk. The prescribing physician sets the regimen.
Can both be used in the same procedure?
Yes — a common strategy is DCB first and a bail-out stent only if the balloon result shows recoil or a flow-limiting dissection.
Related on INVAMED
Portfolio: coronary artery disease & cardiac interventions and peripheral arterial disease.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.